Welcome to our dedicated page for Reata Pharmaceut news (Ticker: RETA), a resource for investors and traders seeking the latest updates and insights on Reata Pharmaceut stock.
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is a clinical-stage biopharmaceutical leader developing innovative therapies for complex diseases through novel molecular targets. This dedicated news hub provides investors and medical professionals with essential updates on the company's therapeutic advancements and strategic developments.
Access timely, verified information about RETA's clinical programs including bardoxolone methyl for chronic kidney disease and omaveloxolone for Friedreich's ataxia. Our curated news collection covers critical updates such as trial results, regulatory communications, research collaborations, and financial disclosures.
Key content areas include NRF2 pathway therapeutic developments, FDA review milestones, partnership announcements with healthcare organizations, and analyses of RETA's position in the biopharmaceutical landscape. All information is sourced from official releases and reputable financial reporting.
Bookmark this page for streamlined access to Reata's progress in addressing unmet medical needs through its groundbreaking approach to cellular metabolism and inflammation resolution. Check back regularly for objective updates that matter to both clinical and investment communities.
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced its participation in the Barclays Global Healthcare Conference from March 14-16 in Miami, Florida. Manmeet Soni, President, COO, and CFO, will engage in a fireside chat at the event. The company is focused on developing innovative therapies for severe diseases and has made significant strides with the first FDA-approved product for Friedreich’s ataxia. Additionally, Reata is advancing its pipeline, including bardoxolone methyl for chronic kidney disease and cemdomespib for diabetic neuropathic pain, although both drugs remain investigational and unproven by regulatory standards.
Reata Pharmaceuticals has announced FDA approval for SKYCLARYS (omaveloxolone) to treat Friedreich’s ataxia in adults and adolescents over 16. This marks the first specific therapy for this ultra-rare, progressive neuromuscular disease affecting approximately 5,000 patients in the U.S. The FDA also granted a rare pediatric disease priority review voucher. The approval is based on data from the MOXIe Part 2 trial, showing significant efficacy and safety. Commercial supply of SKYCLARYS is expected in Q2 2023, alongside the launch of the REACH patient support program.
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) announced its participation in two upcoming healthcare conferences in New York: the Guggenheim 2022 Immunology & Neurology Conference on November 14-15 and the Stifel 2022 Healthcare Conference on November 15-16. As a clinical-stage biopharmaceutical company, Reata focuses on developing innovative therapeutics for serious diseases, with lead candidates omaveloxolone and bardoxolone targeting the Nrf2 transcription factor to combat inflammation and oxidative stress. However, their safety and efficacy remain unverified.
FAQ
What is the market cap of Reata Pharmaceut (RETA)?
